Thus, blocking IFN-αR on tumor cells or an adjunct treatment with Serpin B9 inhibitor (anti-Serpin B9 therapy) can increase cytotoxic CD8+T cells against tumor cells and ICI's antitumor action [186, 187]. Here, IFNAR1 is linked to neoplasm.